Effect of Tamsulosin on Prostate

the Effectiveness of Different Tamsulosin Doses on Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160514027893N3

Enrollment

Registered

2019-04-12

Start date

2018-12-22

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia. Hyperplasia of prostate

Interventions

Intervention 1: First intervention group: .A group that will be received a 0.4 mg tamsulosin capsule of Behestan Pharmaceutical Company once a day for 8 weeks. Intervention 2: Second intervention grou

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: All patients with LUTS (Lower Urinary Tract Symptoms) who need tamsulosin drug and are satisfied.

Exclusion criteria

Exclusion criteria: having prostat surgery history tamsulosin consumption history unsatisfication

Design outcomes

Primary

Measure	Time frame
Reducing the amount of international prostate symptom score (IPSS). Timepoint: Measuring IPSS at the beginning of the study (before the intervention) And 8 weeks after the start of taking tamsulosin capsules. Method of measurement: International prostate symptom score (IPSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Kameli

Bojnourd University of Medical Sciences

ahmad_kamely@yahoo.com+98 58 3222 1910

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026